Tigris Pharmaceuticals Initiates Randomized Phase 2 Study Of AFP-464 In ER-Positive B

[News]

Tigris Pharmaceuticals, Inc., announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex® (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients...

More... (http://www.medicalnewstoday.com/releases/226666.php)